Dr. Sarah Ringold, MD, MS, Director of Clinical Research in Pediatric Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson discusses the US FDA approval of STELARA ® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). Healthcare providers now have access to a first-in-class treatment option – with an established track record of safety and efficacy – for this rare disease that affects five to eight percent of children and adolescents with chronic inflammatory arthritis.
Sarah Ringold MD, MS, Director of Clinical Research in Pediatric Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson
Dr. Ringold is a pediatric rheumatologist currently serving as clinical lead for projects in pediatric rheumatology within Janssen Immunology. Before joining Janssen Immunology in 2021, Dr. Ringold was an Associate Professor at Seattle Children’s where her research focused on juvenile idiopathic arthritis, including disease activity assessment, disease outcomes and the comparative effectiveness of current medical treatments. In her current role, she is serving as the study responsible physician for Phase 3 studies in juvenile psoriatic arthritis. Dr. Ringold completed her MD at Harvard Medical School and her MS in Epidemiology at the University of Washington in Seattle, Washington. She did her residency in pediatrics and her fellowship in pediatric rheumatology at Seattle Children’s, where she maintains affiliate status.